Skip to content

Estrogen Supplementation Mode in HRT-FET Cycle: a RCT

A Multicenter Randomized Controlled Trial Comparing a Step-wise Increase Versus a Constant Dose of Estrogen Supplementation in Frozen-thawed Embryo Transfer Cycles Using Hormone Replacement

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04503915
Enrollment
784
Registered
2020-08-07
Start date
2020-11-01
Completion date
2023-12-01
Last updated
2020-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Estrogen, Hormone Replacement Therapy, Live Birth Rate

Keywords

estrogen supplementation, HRT, Live birth rate

Brief summary

A systematic review and meta-analysis concluded that there is insufficient evidence to recommend one particular protocol for HRT with regard to pregnancy rates after frozen embryo transfer, and no comparison of estrogen dose or route of administration was included in the review\[7\]. It is worth highlighting that the authors did not find any literature discussing the effect of estrogen dose and route of administration for HRT on reproductive outcomes. In 2016, a retrospective cohort study concluded that there is no difference in live birth rates between a constant dose versus an increasing dose of estrogen in oocyte donation cycles with oral or transdermal supplementation\[6\]. In order to provide good evidence about pattern of estrogen supplementation in HRT-FET, a randomized controlled study is urgently needed. The present randomized controlled study aims to compare between a constant estrogen dose protocol and a step-wise increasing estrogen dose protocol on the live birth rate of HRT-FET cycles.

Detailed description

The objective is to compare between a constant estrogen dose protocol and a step-wise increasing estrogen dose protocol on live birth rate of HRT-FET cycles. This is a multicenter randomized controlled trial. Women undergoing HRT-FET will be recruited and randomized to use a constant estrogen dose protocol and a step-wise increasing estrogen dose protocol. Participation in the study is totally voluntary. The subjects can withdraw from the study at any time and they will still receive standard medical care. Women being scheduled for HRT-FET will be assessed for eligibility. Eligible women will be recruited in the study and each woman will only be included in the study once. Informed written consent will be obtained prior to recruitment. The baseline characteristics will be collected. Transvaginal ultrasound will be done to measure the endometrial thickness on the day of progesterone supplementation. Embryo transfer will be performed 3 days or 5 days after progesterone use, depending on replacement of cleaving stage embryos or blastocysts respectively.

Interventions

PROCEDUREdifferent estrogen supplementation modes

The different estrogen supplementation modes are randomized into two groups.

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* Women aged \<42 years at the time of HRT-FET * Replacing 1-2 early cleavage embryos or blastocysts after thawing.

Exclusion criteria

* Preimplantation genetic testing(PGT) * Use of donor oocytes * Hydrosalpinx shown on pelvic scanning and not surgically treated such as tubal ligation or resection * Severe uterine adhesion * The endometrial thickness cannot reach 8mm in previous fresh cycles or HRT -FET cycles

Design outcomes

Primary

MeasureTime frameDescription
live-birth rate per ETUp to 12 monthsLive birth was defined as the delivery of at least one live born baby beyond 28 weeks of gestation.

Secondary

MeasureTime frameDescription
clinical pregnancy rateUp to 6 months\- clinical pregnancy: presence of intrauterine gestational sac on pelvic ultrasound at 6 weeks of gestation

Contacts

Primary ContactHaiyan Lin
709235159@qq.com15913154456
Backup ContactQingxue Zhang
zhangqingxue666@aliyun.com81332233

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026